Immunic, Inc. (NASDAQ:IMUX) Receives $11.20 Consensus PT from Analysts

Immunic, Inc. (NASDAQ:IMUX) has received a consensus rating of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat reports. Five analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $11.20.

A number of equities analysts have recently weighed in on the company. B. Riley initiated coverage on Immunic in a research note on Tuesday, August 27th. They set a “buy” rating and a $6.00 target price on the stock. Piper Sandler reiterated an “overweight” rating and set a $28.00 price objective on shares of Immunic in a research report on Tuesday, July 16th. Leerink Partnrs raised shares of Immunic to a “strong-buy” rating in a research report on Monday, September 9th. StockNews.com upgraded shares of Immunic from a “sell” rating to a “hold” rating in a research note on Tuesday, August 13th. Finally, EF Hutton Acquisition Co. I upgraded shares of Immunic to a “strong-buy” rating in a research note on Monday, September 16th.

Institutional Investors Weigh In On Immunic

Large investors have recently bought and sold shares of the company. Virtu Financial LLC bought a new stake in shares of Immunic during the 1st quarter worth approximately $25,000. Ikarian Capital LLC increased its stake in Immunic by 258.3% in the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after acquiring an additional 1,162,378 shares during the last quarter. Janus Henderson Group PLC acquired a new position in Immunic during the first quarter valued at approximately $9,266,000. BVF Inc. IL bought a new stake in Immunic during the first quarter worth $11,752,000. Finally, Vanguard Group Inc. boosted its holdings in shares of Immunic by 100.7% in the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after purchasing an additional 1,703,047 shares in the last quarter. 51.82% of the stock is currently owned by institutional investors and hedge funds.

Immunic Price Performance

Shares of IMUX opened at $1.21 on Tuesday. The company’s 50-day moving average is $1.50 and its 200-day moving average is $1.35. The firm has a market capitalization of $109.00 million, a PE ratio of -0.81 and a beta of 1.84. Immunic has a fifty-two week low of $0.95 and a fifty-two week high of $2.11.

Immunic (NASDAQ:IMUX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.02. During the same quarter in the prior year, the firm earned ($0.54) earnings per share. Analysts predict that Immunic will post -0.93 earnings per share for the current fiscal year.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.